KR960704842A - 저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물 (Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents) - Google Patents

저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물 (Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents)

Info

Publication number
KR960704842A
KR960704842A KR1019960701555A KR19960701555A KR960704842A KR 960704842 A KR960704842 A KR 960704842A KR 1019960701555 A KR1019960701555 A KR 1019960701555A KR 19960701555 A KR19960701555 A KR 19960701555A KR 960704842 A KR960704842 A KR 960704842A
Authority
KR
South Korea
Prior art keywords
compound
formula
azetidinone
hydroxy
phenyl
Prior art date
Application number
KR1019960701555A
Other languages
English (en)
Other versions
KR100186853B1 (ko
Inventor
비. 로젠블룸 스튜어트
듀가 선딥
에이. 버네트 듀안
더블유. 클라더 죤
에이. 맥키트릭 브라이언
Original Assignee
에릭 에스. 딕커
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960704842(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에릭 에스. 딕커, 쉐링 코포레이션 filed Critical 에릭 에스. 딕커
Publication of KR960704842A publication Critical patent/KR960704842A/ko
Application granted granted Critical
Publication of KR100186853B1 publication Critical patent/KR100186853B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

본 발명은 일반식(Ⅰa)의 하이드록시-치환된 아제티디논 저콜레스테롤혈증제 또는 이의 약제학적으로 허용 되는 염, 이들 화합물을 단독으로 또는 콜레스테롤 생합성 억제제와 배합하여 투여함으로서 혈청 콜레스테롤을 낮추는 방법, 이들 화합물을 함유하는 약제학적 조성물, 및 그들 화합물을 제조하는 방법에 관한 것이다.
상기 식에서Ar1및 Ar2는 아릴 및 R4-환된 아릴이고; Ar3또는 Ar5-치환된 아릴이며; X,Y 및 Z는 -CH2-, CH(저급 알킬)-또는 -C(디저급 알킬)-이고; R 및 R2는 -OR6, -O(CO)R6-O(CO)OR9또는 -O(CO)NR6R7이며; R1및 R3은 수소 또는 저급 알킬이고; q는 0 또는 1이며; r은 0 또는 1이고; m,n 및 p는 0 내지 4이며; 단, q 및 r 중의 하나 이상은 1이고 m,n,p,q 및 r의 합은 1 내지 6이며; p가 0이고 r이 1일때 m,q 및 n의 합은 1 내지 5이고; R4는 저급 알킬, -CF3,-CN, -NO2및 할로겐중에서 선택되고; R5는 -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7,-NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)R7R8, -NR6SO2R9, -COOR6, CONR6R7, - COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10-CONR6R7, -(저급 알킬렌)COOR6및 -CH=CH-COOR6중에서 선택되고; R6, R7및 R8은 수소, 저급 알킬, 아릴 및 아릴-치환된 저급 알킬이며; R9는 저급 알킬, 아릴 또는 아릴-치환된 저급 알킬이다.

Description

저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물(Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 하기 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기 식에서, Ar1및 Ar2는 독립적으로 아릴 및 R4- 치환된 아릴로 이루어진 그룹중에서 선택되고; Ar3은 아릴 또는 R5- 치환된 아릴이며; X,Y 및 Z는 독립적으로 -CH2-, CH(저급 알킬)- 및 -C(디저급 알킬)-로 이루어진 그룹중에서 선택되고;R 및 R2는 독립적으로 -OR6, -O(CO)R6-O(CO)OR9및 -O(CO)NR6R7으로 이루어진 그룹중에서 선택되며; R1및 R3은 독립적으로 수소, 저급 알킬 및 아릴로 이루어진 그룹중에서 선택되고; -q는 0 또는 1이며; r은 0 또는 1이고; m,n 및 p는 독립적으로 0,1,2,3, 또는 4이며; 단, q 및 r 중의 하나 이상은 1이고 m,n,p,q 및 r의 합은 1,2,3,4,5 또는 6이며; p가 0이고 r이 1일때 m,q 및 n의 합은 1,2,3,4 또는 5이며; R4는 독립적으로 저급 알킬, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7,-NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, CONR6R7, - COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10-CONR6R7, -(저급 알킬렌)COOR6-CH=CH=COOR6-CF3,-CN, -NO2및 할로겐으로 이루어진 그룹중에서 선택된 1 내지 5개의 치환체이고; R5는 독립적으로 -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7,-NR6(CO)R7, -NR|6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, CONR6R7, - COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10-CONR6R7, -(저급 알킬렌)COOR6및 -CH=CH=COOR6으로 이루어진 그룹중에서 선택된 1 내지 5개의 치환체이며; R6, R7및 R8은 독립적으로 수소, 저급 알킬, 아릴 및 아릴-치환된 저급 알킬로 이루어진 그룹중에서 선택되고; R9는 저급 알킬, 아릴 또는 아릴-치환된 저급 알킬이다.
  2. 제1항에 있어서 Ar1이 페닐 또는 R4-치환된 페닐이고,Ar2가 페닐 또는 R4-치환된 페닐이며, Ar3이 R5-치환된 페닐인 화합물.
  3. 제2항에 있어서 Ar1이 R4-치환된 페닐(여기서,R6는 할로겐이다)이고, Ar2가 R4-치환된 페닐[여기서,R4는 할로겐 또는 -OR5(여기서, R6는 저급 알킬 또는 수소이다)이다]이며, Ar3이 R5-치환된 페닐[여기서,R5는 -OR6(여기서, R5는 저급 알킬 또는 수소이다)이다]인 화합물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, X,Y 및 Z가 각각 -CH2-이고,R1및 R3가 각각 수소이며, R 및 R2가 각각 -OR5(여기서, R5는 수소이다)이고, m,n,p,q, 및 r의 합이 2,3,또는 4인 화합물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, m,n 및 r이 각각 0이고, q가 1이며, p가 2인 화합물.
  6. 제1항 내지 제4항 중 어느 한 항에 있어서, p,q 및 n이 각각 0이고, r이 1이며, m이 2 또는 3인 화합물.
  7. 제1항에 있어서 rel 3(R)-(2-(R)-하이드록시-2-페닐에틸)-4(R)-(4 메톡시페닐)-1-페닐-2-아제티디논; rel 3(R)-(2-(R)-하이드록시-2-페닐에틸)-4(S)-(4-메톡시페닐)-1-페닐-2-아제티디논; 3(S)-(1-(S)-하이드록시-3-페닐프로필)-4(S)-(4 메톡시페닐)-1-페닐-2-아제티디논;3(S)-(1-(R)-하이드록시-3-페닐프로필)-4(S)-(4 메톡시페닐)-1-페닐-2-아제티디논;3(R)-(1(R)-하이드록시-3-페닐프로필)-4(S)-(4-메톡시페닐)-1-페닐_2-아제티디본;rel-3(R)-[(S)-하이드록시-2-나프탈레닐)메틸]-4(S)-(4-메톡시페닐)-1-페닐-2-아제티디논; rel-3(R)-[(R)-하이드록시-2-나프탈레닐)메틸]4(S)-(4 메톡시페닐)-1-페닐-2-아제티디논; 3(R)-(3(R)-하이드록시-3-페닐프로필)-1,4(S)-비스-(4-메톡시페닐)-1-페닐-2-아제티디논; 3(R)-(3(S)-하이드록시-3-페닐프로필)-1,4(S)-비스-(4-메톡시페닐)-2-아제티디논;4(S)-(4-하이드록시페닐)-3(R)-(3(R)하이드록시-3-페닐프로필)-1-(4-메톡시페닐)-2-아제티디논;4(S)-(4-하이드록시페닐)-3(R)-(3(S)하이드록시-3-페닐프로필)-1-(4-메톡시페닐)-2-아제티디논; rel-3(R)-[3(RS)-하이드록시-3-[4-메톡시메톡시)-페닐]프로필]-1,4(S)-비스-(4-메톡시페닐)-2-아제티디논; 1-(4-플루오로페닐)-3(R)-[3(S)-(4-플루오로페닐)-3-하이드록시프로필)]-4(S)-(4-하이드록시페닐)-2-아제티디논;1-(4-플루오로페닐)-3(R)[3(R)-(4-플루오로페닐)-3-하이드록시프로필)]-4(S)-(4-하이드록시페닐)-2-아제티디논;4(S)-[4-(아세틸옥시)페닐]-3(R)-(3(R)-하이드록시-3-페닐프로필)-1-(4-메톡시페닐)-2-아제티디논;4(S)-[4-(아세틸옥시)페닐]-3(R)-(3(S)-하이드록시-3-페닐프로필)-1-(4-메톡시페닐)-2-아제티디논;1-(4-플루오로페닐)-3(R)-[3(S)-(4-플루오로페닐)-3-하이드록시프로필)]-4(S)-(4-페닐메톡시)페닐]-2-아제티디논;3(R)-[3(R)-(아세틸옥시)-3-페닐프로필]-1,4(S)-비스-(4-메톡시페닐)-2-아제티디논;3(R)-[3(S)-(아세틸옥시)-3-페닐프로필]-1,4(S)-비스-(4-메톡시페닐)-2-아제티디논;3(R)-[3(R)-(아세틸옥시)-3-(4-플루오로페닐)프로필]-4(S)-[4-(아세틸옥시)-페닐]-1-(4-플루오로페닐)-2-아제티디논;3(R)-[3(S)-(아세틸옥시)-3-(4-플루오로페닐)프로필]-4(S)-[4-(아세틸옥시)-페닐]-1-(4-플루오로페닐)-2-아제티디논;3(R)-[3(R)-(아세틸옥시)-3-(4-클로로페닐)프로필]-4(S)-[4-(아세틸옥시)-페닐]-1-(4-클로로페닐)-2-아제티디논;3(R)-[3(S)-(아세틸옥시)-3-(4-클로로페닐)프로필]-4(S)-[4-(아세틸옥시)-페닐]-1-(4-클로로페닐)-2-아제티디논 및 rel 1-(4-플루오로페닐)-4(S)-(하이드록시페닐)-3(R)-(1(R)-하이드록시-3-페닐프로필)-2-아제티디논으로 이루어진 그룹중에서 선택된 화합물.
  8. 약제학적으로 허용되는 담체중에 유효량의 제1항 내지 제7항 중 어느 한 항의 화합물을 단독으로 또는 클레스테롤 생합성 억제제와 배합하여 포함하는, 아테롬성 동맥경화증을 치료 또는 예방하거나 혈장 콜레스테롤 수준을 감소시키기 위한 약제학적 조성물.
  9. 아테롬성 동매경화증을 치료 또는 예방하거나 혈장 콜레스테롤 수준을 감소시키기 위한 약제의 제조에 있어서 제1항 내지 제7항 중 어느 한 항에 따른 화합물의 용도.
  10. 제1항 내지 제7항 중 어느 한 항에 정의된 화합물을 약제학적으로 허용되는 담체와 혼합함을 특징으로 하여, 제8항의 약제학적 조성물을 제조하는 방법.
  11. 제1항 내지 제7항 중 어느 한 항에 정의된 화합물 및 콜레스테롤 생합성 억제제를 약제학적으로 허용되는 담체와 혼합함을 특징으로 하여, 제8항의 약제학적 조성물을 제조하는 방법.
  12. 아테롬성 동매경화증의 치료 또는 예방에서 또는 혈장 클레스테롤 수준 감소를 위한 콜레스테롤 생합성 억제제와의 배합 사용용 약제 제조시 제1항 내지 제7항 중 어느 한 항에 따른 화합물의 용도.
  13. 아테롬성 동매경화증의 치료 또는 예방에서 또는 혈장 클레스테롤 수준 감소를 위한 제1항 내지 제7항 중 어느 한 항에 따른 화합물과의 배합 사용용 약제 제조시 콜레스테롤 생합성 억제제의 용도.
  14. 약제학적으로 허용되는 담체중의 유효량의 콜레스테롤 생합성 억제제를 함유하는 약제학적 조성물을 제1용기에 포함하고 약제학적으로 허용되는 담체중의 유효량의 제1항 내지 제7항 중 어느 한항에 정의된 화합물을 함유하는 약제학적 조성물을 제2용기에 포함하는, 아테롬성 동맥경화증을 치료 또는 예방하거나 혈장 콜레스테롤 수준을 감소시키기 위한 배합 사용용 약제학적 조성물을 단일 팩키지중의 분리 용기에 포함하는 키트.
  15. 제1항 내지 제7항 중 어느 한 항에 정의된 유효량의 화합물을 단독으로 또는 유효량의 콜레스테롤 생합성 억제제와 배합하여 아테롬성 동맥경화증의 치료를 필요로 하는 포유동물에게 투여함을 특징으로 하여, 아테롬성 동맥경화증을 치료 또는 에방하거나 혈장 코레스테롤 수준을 감소시키는 방법.
  16. 제8항, 제11항 또는 제14항에 있어서, 콜레스테롤 생합성 억제제가 HMG CoA환원효소 억제제, 스쿠알렌 합성 억제제 및 스쿠알렌 에폭시다제 억제제로 이루어진 그룹중에서 선택되는 약제학적 조성물.
  17. 제16항에 있어서, 콜레스테롤 생합성 억제제가 로바스타틴, 프라바스타틴, 플루바스타틴, 심바스타틴,CI-981,DMP-565,L-659,699, 스쿠알렌스타틴 1 및 NB-598로 이루어진 그룹중에서 선택되는 약제학적 조성물.
  18. 제12항 또는 제13항에 있어서, 콜레스테롤 생합성 억제제가 제16항 또는 제17항에 정의된 바와 같은 억제제인 용도.
  19. 제15항에 있어서, 콜레스테롤 생합성 억제제가 제16항 또는 제17항에 정의된 바와 같은 억제제인 방법.
  20. (a)일반식(A)의 락톤을 강 염기로 처리하고, (b)단계(a)의 생성물을 일반식
    의 이민(여기서, Ar20은 Ar2,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이고;Ar30은 Ar3,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이다)과 반응시키며,(c)반응물을 산으로 켄칭시키고,(d) R′,Ar10, Ar20및 Ar30으로부터 존재하는 보호그룹을 임의로 제거하며, (e)R3치환체가 부착되어 있는 탄소 및 R에서의 치환기, 및 Ar1, Ar2및 Ar3에서의 하이드록시 또는 아미노 치환기를 임의로 작용화시킴을 특징으로 하여, 일반식(ⅠA)의 화합물을 제조하는 방법.
    상기 식에서,Ar1, Ar2, Ar3,X,Y,Z,R,R1,R3,m,n,p및 q는 제1항에 정의한 바와 같고, 단, m,n,p및 q이 합은 1내지 6이며; R′는 보호된 하이드록시 그룹이고; Ar10은 상기 정의된 바와 같은 Ar1,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이다.
  21. (a)일반식(B)의 락톤을 강 염기로 처리하고, (b)단계(a)의 생성물을 일반식
    의 이민(여기서, Ar20은 Ar2,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이고;Ar30은 Ar3,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이다)과 반응시키며,(c)반응물을 산으로 켄칭시키고,(d) R2′,Ar10, Ar20및 Ar30으로부터 존재하는 보호그룹을 임의로 제거하며, (e)R1치환체가 부착되어 있는 탄소에서의 치환기 및 Ar1, Ar2및 Ar3에서의 하이드록시 또는 아미노 치환기를 작용화시킴을 특징으로 하여, 일반식(ⅠB)의 화합물을 제조하는 방법.
    상기 식에서,Ar1, Ar2, Ar3,X,Y,Z,R,R1,R2,R3,m,n,p및 r은 제1항에 정의한 바와 같고, 단, m,n,p및 r의 합은 1내지 6이며;r 및 n이 각각 0이면, p는 1 내지 4이고; Ar10은 상기 정의된 Ar1,적절히 보호된 하이드록시-치환된 아릴 또는 적절히 보호된 아미노-치환된 아릴이고;R2′는 보호된 하이드록시 그룹이다.
  22. 공정 A:
    일반식(Ⅲ)의 에스테르(여기서,R1,R3,X,Y,Z,m,n,p,q및 r은 제1항에 정의한 바와 같고, R1및 Ar10은 제20항에 정의한 바와 같으며;R2′는 제21항에 정의한 바와 같고; R10은 저급 알킬, 메틸 또는 10-(디이소프로필설폰아미도)이소보르닐이다)를 강 염기로 처리하고, 이어서 일반식(Ⅱ)의 이민(여기서, Ar20및 Ar30은 제20항에 정의한 바와 같다)으로 처리하여 제1항에 정의된 바와 같은 일반식(Ⅰ)의 화합물을 수득하거나;
    공정 B:
    일반식(Ⅴ)의 아제티디논(여기서,Ar20및 Ar30은 제20항에 정의한 바와 같다)을 강 염기로 처리하고, 이어서 일반식(Ⅵ)의 알데하이드 또는 케톤(여기서,R1,R3,X,Y,m,n 및 q는 제1항에 정의한 바와 같고, R′ 및 Ar10은 제20항에 정의한 바와 같다)으로 처리하여 r이 1이고 p가 0이며 R2가 OH인 일반식(I)의 화합물인 일반식 (Ie)의 화합물을 수득하거나;
    공정 C:
    일반식(X)의 화합물(여기서, 변수는 상기 공정 A 및 공정 B에 정의한 바와 같다)을 트리알킬포스핀 및 디알킬아조디카복실레이트로 폐환시켜 일반식(I)의 상대적인 3,4-트란스 화합물인 일반식(Ia)의 화합물을 수득하거나;
    공정 D:
    일반식(Ⅱ)의 이민(여기서,Ar20및 Ar30은 공정 A에 정의한 바와 같다)을 일반식(Ⅶ)의 활성화된 카복실산(여기서, L은 Cl,OP(O)(Cl)OPh,2-옥시-N메틸피리디늄 요오다이드 또는 2-티오피리딜 에스테르이고, 나머지 변수는 공정 A 및 공정 B에 정의한 바와 같다)으로 3급 아민 염기의 존재하에 처리하거나;
    공정 E:
    일반식(ⅩⅢ) 의 화합물(여기서, 변수는 상기 공정 A 및 공정 B에 정의한 바와 같다)을 강 비-친핵성 염기로 처리하여 일반식(I)의 상대적인 3,4-트란스 화합물인 일반식(Ia)의 화합물을 수득하거나;
    공정 F:
    일반식 (ⅩⅥ)의 알데하이드 또는 케톤(여기서, 변수는 상기 공정 A및 공정 B에 정의한 바와 같다)을 Ar10-유기금속성 시약(여기서, Ar10은 상기 공정 A에 정의한 바와 같다)으로 처리하여 R이 OH인 일반식(I)의 화합물인 일반식(Ig)의 화합물을 수득하고, 이어서 보호 그룹을 임의로 제거하거나;
    공정 G:
    일반식(ⅩⅧ)의 화합물(여기서, Hal은 Cl,Br 또는 I이고, Ar1, Ar2, Ar3,R1,R2,R3,Y,Z,q,n,r및 p는 제1항에 정의한 바와 같다)을 테트라알킬-암모늄 염 또는 테트라 n-부틸암모늄 트리플루오로아세테이트로 처리하고, 이어서 온화한 염기로 처리하여 m이 0이고, R이 OH인 일반식(I)의 화합물인 일반식(Ii)의 화합물을 수득하거나;
    공정 H:
    일반식(ⅩⅩ)의 케톤(여기서,Ar10, Ar20, Ar30,R2′,R3,X,Y,Z,m,n,r및 p는 공정 A항에 정의한 바와 같다)을 환원시켜 q가 1이고 R이 OH이며 R1이 H이고 나머지 변수가 일반식(ⅩⅩ)에 정의한 바와 같은 일반식(I)의 화합물인 일반식(Ij)의 화합물을 수득하고, 이어서 보호 그룹을 임의로 제거하거나;
    공정 I:
    일반식(ⅩⅩⅥ) 의 알릴 알콜(여기서,Ar1, Ar2, Ar3및 R1는 제1항에 정의한 바와 같고, X′Y′중 및 하나는 -CH=CH-이고 다른 하나는 -CH=CH-,-CH2-,CH2CH2-,-CH(저급 알킬)-,-CH(디저급 알킬)또는 결합이다)을 수소화하여 Ar1, Ar2, Ar3및 R1이 상기 정의한 바와 같고 X″ 및 Y″중 하나가 -CH2=CH2-이고 다른 하나가 -CH2=CH2-,-CH2-,-CH(저급 알킬)-,-CH(디저급 알킬)또는 결합으로 이루어진 그룹중에서 선택되는 일반식(I)의 화합물인 일반식(Ik)의 화합물을 수득하거나;
    공정 I:
    일반식(ⅩⅩⅨ)의 알콜 (여기서, 변수는 공정 A에 정의한 바와 같다)을 트리스(트리메틸실릴)실란으로 라디칼개시제의 존재하에 탈할로겐화시켜 일반식(Im)및 (In) 의 이성체의 혼합물(여기서, 변수는 상기 정의한 바와 같다)을 수득하고, 이어서 임의로 이성체를 분리하고 보호 그룹을 제거함을 특징으로 하여, 일반식(I)의 화합물을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701555A 1993-09-21 1994-09-14 저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물 KR100186853B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10244093A 1993-09-21 1993-09-21
US8/102440 1993-09-21
US08/102,440 1993-09-21
US08/257,593 1994-06-09
US08/257,593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US8/257593 1994-06-09
PCT/US1994/010099 WO1995008532A1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (2)

Publication Number Publication Date
KR960704842A true KR960704842A (ko) 1996-10-09
KR100186853B1 KR100186853B1 (ko) 1999-05-01

Family

ID=26799377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701555A KR100186853B1 (ko) 1993-09-21 1994-09-14 저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물

Country Status (35)

Country Link
US (5) US5631365A (ko)
EP (1) EP0720599B1 (ko)
JP (1) JP2803908B2 (ko)
KR (1) KR100186853B1 (ko)
CN (1) CN1050830C (ko)
AT (1) ATE180249T1 (ko)
AU (1) AU681445C (ko)
BE (1) BE2014C056I2 (ko)
BR (1) BR1100159A (ko)
CA (1) CA2172149C (ko)
CZ (2) CZ288861B6 (ko)
DE (3) DE10399001I2 (ko)
DK (1) DK0720599T3 (ko)
ES (1) ES2132432T3 (ko)
FI (1) FI110321B (ko)
FR (1) FR05C0040I2 (ko)
GE (1) GEP20043149B (ko)
GR (1) GR3030312T3 (ko)
HU (1) HU221185B1 (ko)
IL (1) IL110956A (ko)
LU (4) LU91050I2 (ko)
MA (1) MA23332A1 (ko)
MY (1) MY111314A (ko)
NL (2) NL300132I2 (ko)
NO (6) NO305902B1 (ko)
NZ (1) NZ274041A (ko)
PL (1) PL182617B1 (ko)
RU (1) RU2138480C1 (ko)
SG (1) SG46208A1 (ko)
SK (1) SK281067B6 (ko)
TN (1) TNSN94094A1 (ko)
TW (1) TW427974B (ko)
UA (1) UA41948C2 (ko)
WO (1) WO1995008532A1 (ko)
ZA (1) ZA947086B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820983B1 (ko) * 2001-01-26 2008-04-10 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (en) * 1994-06-20 1995-12-28 Wayne Vaccaro Substituted azetidinone compounds useful as hypocholesterolemic agents
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69626128T2 (de) * 1995-09-27 2003-11-27 Schering Corp., Kenilworth Stereoselektiver, mikrobieller reduktionsprozess
EP0766962A3 (en) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Treatment of atherosclerosis
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
BR9611401B1 (pt) * 1995-10-31 2010-08-10 2-azetidinonas substituìdas com açúcar úteis como agentes hipocolesterolêmicos, composição farmacêutica e kit contendo as mesmas .
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
EP0939632B1 (en) * 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (fr) * 1997-04-21 1999-06-11 Francois Trantoul Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
JP3640888B2 (ja) * 1998-12-07 2005-04-20 シェーリング コーポレイション アゼチジノンの合成プロセス
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
EP1354604A1 (en) * 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
PL348503A1 (en) * 1998-12-23 2002-05-20 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038721A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
CA2356422C (en) * 1998-12-23 2008-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
AU776953B2 (en) * 1998-12-23 2004-09-30 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
CA2356607A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
CN1249250C (zh) 1999-04-05 2006-04-05 先灵公司 用于制备1－(4－氟苯基)－3(R)－[3(S)－羟基－3－(4－氟苯基)丙基]－4(S)－(4－羟苯基)－2－β丙内酰胺的立体选择性微生物还原反应
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
EP1593670B1 (en) * 2000-12-20 2007-08-08 Schering Corporation Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
HUP0302269A3 (en) * 2000-12-20 2009-08-28 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
BR0116325A (pt) * 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AU2008201609B8 (en) * 2001-01-26 2009-01-08 Organon Llc Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
AU2002247019C1 (en) * 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
DK1353694T3 (da) * 2001-01-26 2008-03-25 Schering Corp Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande
EP1541175A3 (en) * 2001-01-26 2006-04-12 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
JP2004521894A (ja) * 2001-01-26 2004-07-22 シェーリング　コーポレイション 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
DK1373230T3 (da) 2001-03-28 2005-11-07 Schering Corp Enantiselektiv syntese af azetidinon mellemprodukter
ATE345792T1 (de) * 2001-05-25 2006-12-15 Schering Corp Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2003040127A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
IL161741A0 (en) * 2001-11-09 2005-11-20 Atherogenics Inc Methods of reversing and preventingcardiovascular pathologies
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
US20050123580A1 (en) * 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CN1678296A (zh) * 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1626954A2 (en) * 2003-05-05 2006-02-22 Ranbaxy Laboratories, Ltd. Process for the preparation of trans-isomers of diphenylazetidinone derivatives
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
NZ543741A (en) * 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
WO2005009951A2 (en) * 2003-07-24 2005-02-03 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005009955A1 (en) * 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
WO2005042692A2 (en) * 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
JP2007520453A (ja) * 2003-11-10 2007-07-26 マイクロビア インコーポレーテッド ４−ビアリーリル−１−フェニルアゼチジン−２−オン
AU2003282384A1 (en) * 2003-11-24 2005-06-08 Hetero Drugs Limited A novel process for ezetimibe intermediate
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
ES2399721T5 (es) * 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AU2005245124A1 (en) * 2004-05-21 2005-12-01 Sanofi-Aventis Deutschland Gmbh Method for producing 1,4-diphenyl azetidinone derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
PE20060594A1 (es) * 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
CA2592350A1 (en) * 2004-12-15 2006-06-22 Schering Corporation Functional assays for cholesterol absorption inhibitors
US20130082232A1 (en) 2011-09-30 2013-04-04 Unity Semiconductor Corporation Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
EP1865947A1 (en) * 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CA2608108A1 (en) * 2005-05-09 2006-11-16 Microbia, Inc. Organometal benzenephosphonate coupling agents
KR20080017345A (ko) * 2005-05-11 2008-02-26 마이크로비아 인코포레이티드 페놀성 4-비페닐일아제티딘-2-온의 제조방법
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EA200702614A1 (ru) * 2005-05-25 2008-04-28 Майкробиа, Инк. Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
JP2008543837A (ja) * 2005-06-15 2008-12-04 メルク エンド カムパニー インコーポレーテッド 抗高コレステロール血症化合物
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
RU2008102236A (ru) * 2005-06-22 2009-07-27 РЕДДИ Манне САТЬЯНАРАЯНА (IN) Улучшенный способ получения эзетимиб
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
WO2007030721A2 (en) * 2005-09-08 2007-03-15 Teva Pharmaceutical Industries Ltd. Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
CN101291662A (zh) 2005-10-21 2008-10-22 诺瓦提斯公司 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
HU0501164D0 (en) * 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
DE602006009845D1 (de) * 2005-12-22 2009-11-26 Medichem Sa Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
MX2008010235A (es) * 2006-02-16 2008-10-23 Kotobuki Pharmaceutical Co Ltd Metodo para producir alcohol opticamente activo.
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
MX2008011418A (es) * 2006-03-06 2008-09-22 Teva Pharma Composiciones de ezetimibe.
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
US20080032964A1 (en) * 2006-04-10 2008-02-07 Kansal Vinod K Process for the synthesis of azetidinone
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
JP2009503119A (ja) * 2006-08-29 2009-01-29 テバ ファーマシューティカル インダストリーズ リミティド （３ｒ，４ｓ）−４−（４−ヒドロキシ保護−フェニル）−１−（４−フルオロフェニル）−３−［３−（４−フルオロフェニル）−３−オキソプロピル］アゼチジン−２−オンを精製する方法
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CN101528227A (zh) * 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
JP2010503679A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN100564357C (zh) * 2006-10-20 2009-12-02 浙江天宇药业有限公司 一种氮杂环丁酮衍生物及其合成方法
WO2008085300A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1939174A1 (en) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
EA017349B1 (ru) * 2007-01-24 2012-11-30 Крка Способ получения эзетимиба и его производных
WO2008096372A2 (en) * 2007-02-06 2008-08-14 Ind-Swift Laboratories Limited Process for preparing highly pure ezetimibe using novel intermediates
WO2008104875A1 (en) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
EP2133347A4 (en) 2007-03-06 2010-03-17 Teijin Pharma Ltd 1-BIARYLAZETIDINONDERIVATE
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2009027785A2 (en) * 2007-08-30 2009-03-05 Pfizer Products Inc. 1, 3-oxazole derivatives as cetp inhibitors
WO2009032264A1 (en) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing intermediates of ezetimibe by microbial reduction
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2217214B1 (en) 2007-12-10 2017-07-19 ratiopharm GmbH Pharmaceutical formulation comprising ezetimibe
CZ305066B6 (cs) * 2008-02-25 2015-04-22 Zentiva, K.S. Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
CA2724873A1 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
SI2329014T1 (sl) 2008-08-29 2015-01-30 Codexis, Inc. Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
MX2011005077A (es) 2008-11-14 2011-05-25 Bomi P Framroze Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
ATE536172T1 (de) 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As Ezetimibzusammensetzungen
EP2414326B1 (en) 2009-03-31 2017-12-20 Lupin Limited Intermediates in the preparation of 1,4-diphenyl azetidinone
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
WO2011002422A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
ES2575560T3 (es) 2009-08-19 2016-06-29 Codexis, Inc. Polipéptidos cetorreductasa para preparar fenilefrina
AU2011220748B2 (en) 2010-02-24 2015-11-05 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
BR112012021444A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
JP5964247B2 (ja) 2010-02-24 2016-08-03 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するためのポリイミダゾール
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
PT3205351T (pt) 2010-04-23 2023-06-28 Alexion Pharma Inc Enzima de doença de armazenamento lisossomal
EP2566497B1 (en) 2010-05-04 2015-07-29 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2372460B1 (es) 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
CN105457018A (zh) 2010-09-09 2016-04-06 辛那杰瓦生物制药股份有限公司 使用溶酶体酸性脂肪酶来治疗患者的溶酶体酸性脂肪酶缺乏
HUE030062T2 (en) 2010-11-08 2017-04-28 Albireo Ab IBAT inhibitors for the treatment of liver diseases
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
WO2012076030A1 (en) 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
PL231215B1 (pl) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
CN102675177A (zh) * 2011-06-28 2012-09-19 常州制药厂有限公司 一种降血脂药物及其关键中间体的制备方法
CN102952055A (zh) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 一种依泽替米贝和其中间体的制备方法
CN103204795B (zh) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 一种手性氮杂环丁酮类化合物的制备方法
PL2844233T3 (pl) 2012-05-01 2020-09-07 Althera Life Sciences, Llc Preparat w postaci tabletki do stosowania doustnego składający się ze stałego połączenia rosuwastatyny i ezetymibu w leczeniu hiperlipidemii i chorób sercowo-naczyniowych
CN103570574B (zh) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 一种依泽替米贝的合成方法及该方法中所用的中间体
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
CN103864708A (zh) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 一种依折麦布中间体的制备方法
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
US9926269B2 (en) 2013-12-18 2018-03-27 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
CN103739537B (zh) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 依折麦布的新合成方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN103755616A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种制备依泽替米贝异构体的方法
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104447474A (zh) * 2014-11-11 2015-03-25 武汉武药科技有限公司 一种依折麦布异构体的合成方法
CN104387308A (zh) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
JP2016145173A (ja) * 2015-02-09 2016-08-12 株式会社トクヤマ （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐（４‐ヒドロキシフェニル）‐２‐アゼチジノンの製造方法
CN114099496A (zh) 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN105287513A (zh) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 一种依折麦布药物组合物及其制备方法
CN107098841A (zh) * 2016-02-19 2017-08-29 常州方楠医药技术有限公司 一种依折麦布的制备方法及该方法中所用的中间体
CN109791797B (zh) 2016-12-05 2023-05-02 智慧芽信息科技(苏州)有限公司 在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
EP3740653A4 (en) 2018-01-16 2021-10-20 Q.E.D. Environmental Systems, Inc. LIQUID LEVEL MONITORING SYSTEM AND METHOD WITH A PRESSURE SENSOR SYSTEM WITH INFLATABLE / FOLDABLE BAG
EP3942047A1 (en) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
CN113727732B (zh) 2019-03-20 2023-08-08 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
WO2022023206A1 (en) 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
AU2022291920A1 (en) * 2021-06-17 2023-12-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Hybutimibe intermediate and preparation method therefor
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
IL65158A0 (en) 1981-03-09 1982-05-31 Lilly Co Eli Azetidinones
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
GR81665B (ko) 1983-02-02 1984-12-12 Univ Notre Dame Du Lac
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4565654A (en) 1983-03-28 1986-01-21 University Of Notre Dame Du Lac N-Acyloxy monocyclic β-lactams
WO1985004876A1 (en) 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4581170A (en) 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
EP0232017A1 (en) 1986-01-23 1987-08-12 The Upjohn Company Antimicrobial N-acyl-2-azetidinones
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
JPH0645656B2 (ja) 1988-06-16 1994-06-15 出光石油化学株式会社 スチレン系共重合体およびその製造方法
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1992018462A1 (en) 1991-04-12 1992-10-29 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
GB2264707A (en) 1991-06-18 1993-09-08 Roger Michael Marchbanks Acridine derivatives for treating alzheimer's disease
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
CA2114007C (en) 1991-07-23 2005-12-20 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
ES2107548T3 (es) * 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
JP2620437B2 (ja) * 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5321031A (en) 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
WO1994017036A1 (en) 1993-01-22 1994-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents
TW270118B (ko) 1993-02-26 1996-02-11 Schering Corp
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
AU681419B2 (en) 1993-07-09 1997-08-28 Schering Corporation Process for the synthesis of azetidinones
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
EP0855396A1 (en) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
EP1056455A1 (en) 1998-02-20 2000-12-06 Avmax, Inc. Epimorphian compound and its use
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
NZ518822A (en) 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
CZ20023223A3 (cs) 2000-04-07 2003-12-17 Pfizer Products Inc. Metabolity s agonisty/antagonisty estrogenu
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820983B1 (ko) * 2001-01-26 2008-04-10 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CZ288891B6 (cs) 2001-09-12
CA2172149C (en) 2000-11-28
PL182617B1 (pl) 2002-02-28
CZ83996A3 (en) 1996-08-14
BE2014C056I2 (en) 2018-02-05
CN1050830C (zh) 2000-03-29
FI961300A0 (fi) 1996-03-21
EP0720599B1 (en) 1999-05-19
CN1131416A (zh) 1996-09-18
MA23332A1 (fr) 1995-04-01
WO1995008532A1 (en) 1995-03-30
LU92545I2 (fr) 2015-09-21
USRE42461E1 (en) 2011-06-14
UA41948C2 (uk) 2001-10-15
NO961133L (no) 1996-03-20
NO2017042I1 (no) 2017-08-02
ATE180249T1 (de) 1999-06-15
NZ274041A (en) 1997-12-19
GEP20043149B (en) 2004-01-12
NO2003007I2 (no) 2005-08-29
AU681445C (en) 2004-07-08
IL110956A (en) 2001-01-11
ES2132432T3 (es) 1999-08-16
PL313589A1 (en) 1996-07-08
TNSN94094A1 (fr) 1995-04-25
CZ288861B6 (cs) 2001-09-12
BR1100159A (pt) 2006-09-26
DE122004000026I2 (de) 2005-09-29
AU681445B2 (en) 1997-08-28
IL110956A0 (en) 1994-11-28
SG46208A1 (en) 1998-02-20
JP2803908B2 (ja) 1998-09-24
FR05C0040I2 (fr) 2006-12-29
NL300172I1 (nl) 2005-04-01
TW427974B (en) 2001-04-01
MY111314A (en) 1999-10-30
GR3030312T3 (en) 1999-09-30
NL300132I2 (nl) 2003-11-03
LU92544I2 (fr) 2015-01-20
DK0720599T3 (da) 1999-11-08
NO305902B1 (no) 1999-08-16
HU9600697D0 (en) 1996-05-28
LU91160I2 (fr) 2005-11-25
DE69418613D1 (de) 1999-06-24
AU7795294A (en) 1995-04-10
HUT73852A (en) 1996-09-30
FI110321B (fi) 2002-12-31
EP0720599A1 (en) 1996-07-10
US5846966A (en) 1998-12-08
RU2138480C1 (ru) 1999-09-27
DE69418613T2 (de) 1999-09-30
USRE37721E1 (en) 2002-05-28
DE122004000026I1 (de) 2004-11-18
NL300172I2 (nl) 2005-08-01
US5631365A (en) 1997-05-20
FR05C0040I1 (ko) 2005-10-28
KR100186853B1 (ko) 1999-05-01
NO2005003I2 (no) 2005-10-03
NO961133D0 (no) 1996-03-20
HU221185B1 (en) 2002-08-28
JPH08509989A (ja) 1996-10-22
NL300132I1 (nl) 2003-10-01
SK35596A3 (en) 1997-02-05
NO2014022I1 (no) 2014-09-10
ZA947086B (en) 1995-03-14
NO2014023I1 (no) 2014-09-12
LU91050I2 (fr) 2004-10-12
SK281067B6 (sk) 2000-11-07
DE10399001I1 (de) 2003-06-12
FI961300A (fi) 1996-03-21
DE10399001I2 (de) 2012-05-16
NO2005003I1 (no) 2005-02-28
US5767115A (en) 1998-06-16

Similar Documents

Publication Publication Date Title
KR960704842A (ko) 저콜레스테롤혈증제로서 유용한 하이드록시-치환된 아제티디논 화합물 (Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents)
RU96110282A (ru) Замещенные гидроксилом азетидиноны, пригодные в качестве гипохолестеринемического средства
US8178665B2 (en) Process for the production of ezetimibe and intermediates used in this process
US20090227786A1 (en) Processes for preparing intermediate compounds useful for the preparation of ezetimibe
US4897402A (en) 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
EP1539734B1 (fr) Derives de la quinolyl propyl piperidine et leur utilisation en tant qu'agents antimicrobiens
US4992429A (en) Novel HMG-COA reductase inhibitors
NZ283528A (en) Azetidinone derivatives; medicaments; precursors
HU218222B (hu) Karba-penem-származékok, valamint ilyeneket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP4524111B2 (ja) ＨＭＧ−ＣｏＡ還元酵素阻害剤の製造法
EP0106652B1 (en) Beta-lactam compounds and production thereof
IE842848L (en) Producing penems
US4138403A (en) Azabicycloheptanes
JPS611681A (ja) ３，４，５，６‐テトラヒドロ‐２ｈ‐ピラン‐２‐オンのｃ↓６でのエピ化方法
US5831091A (en) Process for preparing acetoxyazetidinone derivative and intermediate thereof
AU622342B2 (en) Imino-substituted pyridines
US5169976A (en) N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
JPH0135823B2 (ko)
US5196528A (en) 4-cyclohexenyl azetidinones and epoxy derivatives thereof
US5075439A (en) Processes for (3S,4R)-3-[1(R)-t-butyl-dimethylsilyloxy)-ethyl]-4-[1-oxo-3-thiolanylthio(thiocarbonyl)thio]azetidin-2-ones and intermediates therefor
JP2899707B2 (ja) β―ラクタム系化合物の製造法
EP0422102A1 (en) 5-OXA, 5-THIA, 5-AZA HMG-CoA REDUCTASE INHIBITORS
JPH0770116A (ja) ４−置換アゼチジノン誘導体の製造方法
HU211327A9 (hu) 10-(1 -Hidroxi-etil)-11 -oxo-1-azatriciklo [7.2.0.03.8]undec-2-én-karbonsav-származékok Az átmeneti oltalom az 1-8., 16., 17. igénypontokra vonatkozik.
IE910495A1 (en) IMPROVED PROCESSES FOR¹(3S'4R)-3-[1(R)-(t-BUTYLDIMETHYLSILYLOXY)ETHYL]-4-[1-OXO-3-¹THIOLANYLTHIO(THIOCARBONYL)THIO]-AZETIDIN-2-ONES AND¹INTERMEDIATES THEREFOR

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20140929

Year of fee payment: 17

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 18

J206 Request for trial to confirm the scope of a patent right
J206 Request for trial to confirm the scope of a patent right
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160204

Effective date: 20160422

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160202

Effective date: 20160422

Free format text: TRIAL NUMBER: 2016100000301; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160202

Effective date: 20160422

Free format text: TRIAL NUMBER: 2016100000321; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160204

Effective date: 20160422

Free format text: TRIAL NUMBER: 2016100000424; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160219

Effective date: 20160422

EXPY Expiration of term